Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ismat Lotia‐Farrukh; Nathalie Lachenal; Malik M Adenov; Saman Ahmed; Yerkebulan Algozhin; Sylvine Coutisson; Epifanio Sánchez Garavito; Catherine Hewison; David Holtzman; Helena Huerga; Aleeza Janmohamed; Palwasha Khan; Gamarly Leblanc Jacques; Nino Lomtadze; Nara Melikyan; Carole D. Mitnick; Gulnaz Mussabekova; Elna Osso; Sara Perea; Fauziah Asnely Putri; Mahmud Rashidov; Michael Rich; Yekaterina Sakhabutdinova; Kwonjune J. Seung; Assel Stambekova; Dante Vargas Vásquez; Molly F. Franke; Uzma Khan

doi:10.1093/cid/ciad445

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lotia‐Farrukh et al. (2023) studied this question.

synapsesocial.com/papers/69dbebfbd60f0b8828835b43 https://doi.org/10.1093/cid/ciad445

View Full Paper

Ask AI

Bookmark

Share

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ask about this paper

Abstract

Discussion

Cite This Study

Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading